Cookson Peirce & Co. Inc. Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Cookson Peirce & Co. Inc. bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,034 shares of the company’s stock, valued at approximately $700,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IDXX. EverSource Wealth Advisors LLC grew its holdings in IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after buying an additional 15 shares in the last quarter. Harbour Investments Inc. grew its holdings in IDEXX Laboratories by 13.3% during the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after buying an additional 16 shares in the last quarter. CWA Asset Management Group LLC grew its holdings in IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after buying an additional 17 shares in the last quarter. Stratos Wealth Partners LTD. grew its holdings in IDEXX Laboratories by 1.7% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after buying an additional 18 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC grew its holdings in IDEXX Laboratories by 11.5% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after buying an additional 18 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX stock opened at $562.16 on Monday. The firm has a fifty day moving average price of $563.05 and a 200 day moving average price of $631.88. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm has a market cap of $44.34 billion, a PE ratio of 41.40, a price-to-earnings-growth ratio of 3.08 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the firm posted $2.91 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on IDXX shares. UBS Group cut their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.